Coloplast A/S (NASDAQ:CLPBY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The brokerage currently has a $9.00 target price on the stock.

According to Zacks, “Coloplast A/S develops and provides health care products and services. Its operating business segments consist of Chronic Care, Urology Care and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Urology Care segment offers urological products, including disposable products. The Wound and Skin Care segment covers the sale of wound and skin care products. Coloplast A/S is headquartered in Humlebaek, Denmark. “

Coloplast A/S (NASDAQ CLPBY) traded up 1.37% during mid-day trading on Friday, hitting $8.12. The stock had a trading volume of 46,370 shares. Coloplast A/S has a 1-year low of $6.14 and a 1-year high of $8.84.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/22/coloplast-as-clpby-upgraded-by-zacks-investment-research-to-buy.html.

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.